

Therapeutic Apheresis Industry Predicted to Hit US\$ 5,264.4 Million by 2033 with 6.8% CAGR | Future Market Insights Inc.

Rising diseases, demand for blood components, safety, tech advancements, and support drive the Therapeutic Apheresis Industry.



NEWARK, DELAWARE, UNITED STATES OF AMERICA, November 9, 2023 /EINPresswire.com/ -- The global [Therapeutic Apheresis Industry](#) is poised for a CAGR of 6.8% over the forecast period. With a projected value of US\$ 2,717.9 million in 2023, the market's influence is set to double, reaching an impressive US\$ 5,264.4 million by 2033. This substantial expansion underscores the increasing demand for therapeutic apheresis solutions worldwide.

The rising prevalence of diseases, increased demand for blood components, and the safety that goes along with them are the key components for market growth. Moreover, technological advancements in creating new apheresis techniques and increasing reimbursement policies and funding are market-driving forces.

In addition, the market expansion is anticipated to be fueled by the increased incidence of blood-related illnesses, the availability of supportive government initiatives, and reimbursement frameworks. Moreover, it is projected that the demand for apheresis equipment will be supported throughout the forecast period by the increased popularity and involvement in blood donation campaigns and camps and the rising number of blood transfusions.

Request a Sample of this Report Now!

<https://www.futuremarketinsights.com/reports/sample/rep-gb-5863>

The expansion of the North American Therapeutic Apheresis Industry is anticipated to be constrained by the need for more donor availability and histocompatibility. For instance, barely 3% of Americans give blood, according to a June 2019 article from the American Red Cross.

Therapeutic Apheresis Industry Key Takeaways

By 2033, the Therapeutic Apheresis Industry in the United Kingdom will likely expand, with a CAGR of 4.8%.

In 2022, the United States developed the therapeutic apheresis business with a share of 28.8%.

The Therapeutic Apheresis Industry grew considerably to US\$ 2,577.9 million in 2022.

The therapeutic apheresis sector expanded at a CAGR of 4.4% from 2018 to 2022.

By 2033, China's Therapeutic Apheresis Industry is projected to develop with a CAGR of 8.3%.

By 2033, India's therapeutic apheresis industry is projected to expand with a CAGR of 6.8%.

Japan's therapeutic apheresis industry grew significantly, with a 4.2% share in 2022.

Australia's Therapeutic Apheresis Industry is likely to expand with a CAGR of 6.1% by 2033.

Germany's therapeutic apheresis business grew, with a share of 6.3% in 2022.

In 2022, based on the technology, centrifugation dominated the market, with a share of 58.3%.

In 2022, the blood bank segment dominated the market, with a share of 43.5%, based on end users.

Therapeutic Apheresis Industry Competitors and Their Winning Strategies

The market has currently demonstrated budding success and is well-established in several locations. As a result of growing government activities, more individuals are becoming aware of the industry under study, fueling its expansion. Strategic partnerships and new product launches by large corporations are also anticipated to fuel market expansion.

Methodology Details Just a Click Away!

<https://www.futuremarketinsights.com/request-report-methodology/rep-gb-5863>

Top 13 Players in Therapeutic Apheresis Industry:

Asahi Kasei Medical Co.
Haemonetics Corporation
Miltenyi Biotec
Cerus Corporation
Terumo BCT Inc.
Fresenius Kabi USA
Terumo Bct
Braun Melsungen AG
Nikkiso Co. Ltd.
Medica S.p.A.

Baxter Healthcare Corporation
Kawasumi Laboratories Inc.
Therakos Incorporation

Therapeutic Apheresis Industry Recent Developments:

Toray Medical Co. Ltd. (Japan) introduced the TORAYMYXIN medical device to the European market in June 2019.

Baxter International Inc. (United States) introduced the PrisMax system in the US in July 2019.

In June 2022, Terumo Blood and Cell Technologies announced that the automated red blood cell exchange procedure performed on the company's Spectra Optia Apheresis System had been selected by the NHS MedTech Funding Mandate (MTFM) programme in NHS England in the United Kingdom to treat sickle cell disease.

In July 2022, Eliaz Therapeutics and Terumo Blood and Cell Technologies worked together to create and market a breakthrough therapeutic apheresis therapy for acute renal damage (AKI).

Access Exclusive Market Insights - Purchase Now!

<https://www.futuremarketinsights.com/checkout/5863>

Therapeutic Apheresis Industry Key Segments

By Procedure Types:

Therapeutic Plasma Exchange (TPE)
Red Blood Cell Exchange (RBCX)
Cellular Depletions

By Technology:

Centrifugation
Membrane filtration

By Application:

Hematology
Neurology
Nephrology
Rheumatology
Oncology
Others

By End User:

Hospitals
Blood banks
Specialty clinics

By Region:

North America
Latin America
Asia Pacific
MEA
Europe

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

Have a Look at Related Reports of Covered in Therapeutic Apheresis Industry:

[Leukemia Therapeutics Treatment Market](#) valuation is US\$ 15,246.7 million in 2023. In 2022, the value was US\$ 14,504.8 million. The market is predicted to grow at a healthy CAGR of 7.1% from 2023 to 2033.

[Lung Cancer Therapeutics Market](#) share is projected to reach US\$ 48,725.9 Million by 2026, exhibiting a CAGR of 13.4% in the forecast period.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market

intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Ankush Nikam

Future Market Insights, Inc.

+91 90966 84197

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/667335878>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.